Evidence map›Paper›PMID 35861718›Full record

ArticleNucleic acid therapeutics2022

Inhibition of Epidermal Growth Factor Receptor Signaling by Antisense Oligonucleotides as a Novel Approach to Epidermal Growth Factor Receptor Inhibition.

Thushara W Madanayake, Eric A Welsh, Lancia N F Darville, John M Koomen, Charles E Chalfant, Eric B Haura, Timothy J Robinson

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nucleic acid therapeutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Thushara W MadanayakeDepartment of Thoracic Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA.ORCID 0000-0002-6162-9430
Eric A WelshDepartment of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA.
Lancia N F DarvilleDepartment of Proteomics and Metabolomics Core, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA.
John M KoomenDepartment of Molecular Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA.
Charles E ChalfantDepartment of Cell Biology and Medicine, School of Medicine, University of Virginia, Charlottesville, Virginia, USA.
Eric B HauraDepartment of Thoracic Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA.
Timothy J RobinsonDepartment of Therapeutic Radiology, Yale School of Medicine, New Haven, Connecticut, USA.

Funding

TRANSLATIONAL RESEARCHP30CA076292 · NCI · UNIVERSITY OF SOUTH FLORIDA · PI Christine O'Connell · 1998 to 2026
$93.5M
The roles of ceramide and its derivatives in A. phagocytophilum pathogenesisR01AI139072 · NIAID · VIRGINIA COMMONWEALTH UNIVERSITY · PI CHARLES E. CHALFANT, Jason A Carlyon · 2018 to 2026
$5.7M
iPLA2beta-mediated alternative splicing and -cell death in type 1 diabetesR01DK126444 · NIDDK · UNIVERSITY OF VIRGINIA · PI CHALFANT, CHARLES E., EIZIRIK, DECIO LAKS · 2021 to 2024
$2.0M
The role of RNA splicing in non-small cell lung cancerI01BX001792 · VA · VA VETERANS ADMINISTRATION HOSPITAL · PI CHALFANT, CHARLES E. · 2013 to 2024
–
BLRD Research Career Scientist Award ApplicationIK6BX004603 · VA · VA VETERANS ADMINISTRATION HOSPITAL · PI CHALFANT, CHARLES E. · 2019 to 2025
–
BLRD VA I01 BX001792BLRD VA IK6 BX004603NCI NIH HHS P30 CA076292NIAID NIH HHS R01 AI139072NIDDK NIH HHS R01 DK126444
6 · The paper itself

Abstract

We report a novel method to inhibit epidermal growth factor receptor (EGFR) signaling using custom morpholino antisense oligonucleotides (ASOs) to drive expression of dominant negative mRNA isoforms of EGFR by ASO-induced exon skipping within the transmembrane (16) or tyrosine kinase domains (18 and 21).

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsCell Line, TumorDrug Resistance, NeoplasmErbB ReceptorsErlotinib HydrochlorideHumansMorpholinosMutationOligonucleotides, AntisenseProtein Kinase InhibitorsProto-Oncogene Proteins c-aktRNA IsoformsSignal TransductionErbB ReceptorsErlotinib HydrochlorideMorpholinosOligonucleotides, AntisenseProtein Kinase InhibitorsProto-Oncogene Proteins c-aktRNA Isoformsantisense oligonucleotidesepidermal growth factor receptorexon skippingreceptor tyrosine kinasetyrosine kinase inhibitors

Identifiers

PMID35861718
PMCPMC9595651

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.